Evaluation of the Antioxidant and Anti-Inflammatory Capacities of the 'Rosy Red Valencia' and 'Olinda Valencia' Sweet Orange Varieties in Healthy Subjects
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Apr 17, 2025
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the health benefits of two types of sweet oranges—'Rosy Red Valencia' and 'Olinda Valencia'—to see how they affect inflammation and oxidative stress in healthy adults. The 'Rosy Red Valencia' variety is rich in certain natural compounds called carotenoids, which may help protect the body from damage and inflammation, while the 'Olinda Valencia' does not have these compounds. Over four weeks, participants will eat these oranges daily, and researchers will look at how this affects their health markers, including blood samples and gut health.
To participate, you should be a healthy adult between 25 and 40 years old, with a body mass index (BMI) between 21 and 29.9. You'll need to be willing to stop eating certain foods and supplements during the study. Unfortunately, if you are pregnant, have certain medical conditions, or follow specific diets like vegan or vegetarian, you won't be eligible. Participants can expect to contribute blood and stool samples and will help researchers understand the potential health benefits of different orange varieties. This study could provide valuable insights into how specific nutrients in fruits can impact our health.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Healthy men and women
- • Age Range: 25-40 years
- • Body mass index (BMI) with values between 21 and 29.9 kg\^m2
- • Willingness to accept randomization, undergo the testing and intervention procedures, and deliver blood and stool samples
- • Willingness to refrain from consuming foods rich in lycopene, phytoene, and phytofluene and limit the intake of some polyphenol-rich foods
- • Willingness to discontinue the use of antioxidant supplements (such as carotenoid, polyphenol supplements), prebiotics and/or probiotics
- Exclusion Criteria:
- • Pregnancy/lactation
- • History of cardiovascular diseases, diabetes, uncontrolled hypertension, heart failure, stroke, liver, gallbladder, kidney, thyroid disease, gastrointestinal, autoimmune disorder, or cancer.
- • Psychiatric disease that interferes with the understanding and implementation of the intervention
- • History of eating disorders (such as bulimia nervosa and anorexia nervosa) in the last 5 years
- • Current smokers
- • Vegan, vegetarian, or other special diets (e.g., keto, paleo)
- • Use of antibiotics or laxatives in the previous month
- • History of substance abuse or alcohol abuse
- • involvement in a weight loss intervention program within the past month or weight change \> 10%
- • Self-report of allergic reactions to study products or their phytochemicals.
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Davis, California, United States
Patients applied
Trial Officials
Gerardo G Macknezie, PhD
Study Director
Univeristy of California Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported